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OBJECTIVES We sought to assess the influence of peritransplant ischemia and fibrosis on the development
of allograft vasculopathy, acute cellular rejection and long-term outcome.
BACKGROUND Allograft vasculopathy is a common long-term complication of cardiac transplantation. One
of the potential risk factors is peritransplant allograft ischemia.
METHODS One hundred forty heart transplant recipients had baseline and one-year intravascular
ultrasound analysis done to assess the progression of allograft vasculopathy. Serial endomyo-
cardial biopsies were evaluated for cellular rejection, vascular rejection, ischemia and fibrosis.
Based on histology, patients were classified into one of the following groups: nonischemic
(n 32), ischemia (n 24), fibrosis (n 62) or vascular rejection (n 22). Three-color flow
cytometry crossmatching (FCXM) was used to assess donor-specific human lymphocyte
antigens (HLA) sensitization. Long-term outcome of patients in each group was assessed by
estimating incidence of graft failure or deaths over a seven-year follow up.
RESULTS Patients in the fibrosis group had the lowest incidence of donor-specific HLA sensitization
(40%, p  0.008) and lowest average episodes of cellular rejection (1.7  1.4, p  0.04), but
they had increased coronary vasculopathy progression (change in coronary intimal thickness 
0.59  0.28 mm, p  0.0001) and poor seven-year event-free survival (49%, p  0.01).
CONCLUSIONS The development of fibrosis after cardiac transplantation is associated with advanced coronary
vasculopathy, although a low incidence of acute cellular rejection is noted, suggesting the
presence of nonimmune mechanisms in mediating the pathogenesis of allograft
vasculopathy. (J Am Coll Cardiol 2002;39:970–7) © 2002 by the American College of
Cardiology Foundation
Allograft vasculopathy is a significant long-term complica-
tion of cardiac transplantation. Angiographically evident
allograft vasculopathy affects up to half of the heart trans-
plant recipients who survive five years after transplantation
(1). Necropsy and intravascular ultrasound (IVUS) studies
have demonstrated that angiography underestimates trans-
plant coronary artery disease (2–4). Donor and recipient
age, serum triglyceride and cholesterol levels, major histo-
compatability mismatch, alloantigen-dependent cellular and
vascular rejection, cytomegalovirus infection and ischemia
time have all been suggested as risk factors for the develop-
ment of allograft vasculopathy, but the role of these risk
factors has not been fully established (1,5–11).
See page 978
Ischemia-induced myocardial injury is a well-defined
histopathological pattern seen in endomyocardial biopsies
soon after transplantation. Graft ischemia time, peritrans-
plant hemodynamic status of the donor, inotropic support
required by the donor, myocardial damage due to reperfu-
sion and the quality of graft preservation during transpor-
tation play a role in the pathogenesis of ischemic injury
(12–14). Ischemic injury to the heart at the time of
transplantation might influence the development of accel-
erated allograft atherosclerosis through a number of mech-
anisms, including endothelial cell injury and promotion of
cellular and vascular rejection through the release of donor
antigens (15). Myocardial fibrosis after ischemia may also
influence the allograft. The purpose of this study was to
evaluate the impact of peritransplant myocardial ischemic
injury on allograft vasculopathy and long-term survival in
heart transplant recipients.
METHODS
Patient population. Between December 1992 and Decem-
ber 1997, a total of 422 patients underwent heart transplan-
tation at The Cleveland Clinic Foundation. One hundred
forty of these transplant recipients had a baseline IVUS
study at one month of transplant and participated in a
prospective 12-month study. All patients gave informed
consent. Information regarding donor and recipient age, the
etiology of heart failure in the recipient, the mode of donor
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death, ischemia time and use of left ventricular assist device
was obtained from The Cleveland Clinic Foundation Car-
diac Transplant Database. The patients were followed for a
period of 67 19 months after transplantation to assess the
incidence of graft failure, retransplantation and death.
IVUS. Intravascular ultrasound was performed in 294 cor-
onary vessels in 140 patients (2.1  0.6 arteries/patient).
The methods of IVUS imaging have been previously re-
ported in detail (16). Briefly, the ultrasound catheter was
passed over an angioplasty guidewire to the most distal
position that could be safely reached, and the distal site was
documented by cineangiography. Ultrasound images were
recorded on a super VHS tape during a slow distal to
proximal pull back. When necessary, a repeat imaging was
performed to concentrate on specific regions of interest, and
contrast was injected to confirm the location of the imaging
site to enable precise matching on a follow-up study. Before
the one-year follow-up examination, the cineangiograms
and IVUS images from the baseline study were reviewed by
operators to duplicate the imaging study. Coronary intimal
thickness was measured at baseline (1.0  0.1 months) and
one year (12.0  1.0 months) after transplantation (Fig. 1).
Paired analysis of matched sites (10 sites/patient) at one year
measured the change in maximal intimal thickness (CMIT).
Intimal thickening of 0.3 mm was considered pathologi-
cal, based on reported values of intimal thickness in the
young adult population (17,18). Development of coronary
vasculopathy progression was defined as an increase in
CMIT 0.3 mm at any site in one year.
Endomyocardial biopsies. An average of 13 biopsies was
performed in each patient during the first year after trans-
plantation as part of the routine endomyocardial biopsy
protocol to monitor for acute rejection. During each proce-
dure, four or five tissue specimens were usually obtained.
The tissues were evaluated for ischemic injury, cellular and
vascular rejection, and for development of interstitial fibrosis
(Fig. 2). Ischemic injury related to transplantation was
identified by areas of myocyte necrosis occurring in the
immediate post-transplant period with an absence of infil-
tration by activated lymphocytes (12–14). Ischemia was
noted within two weeks of transplantation. Biopsies that
showed scarring consistent with old biopsy site in the
absence of interstitial fibrosis were not considered part of
Abbreviations and Acronyms
CMIT  change in maximal intimal thickness
FCXM flow cytometry cross match
HLA  human lymphocyte antigens
IVUS  intravascular ultrasound
Figure 1. In vivo intravascular ultrasound images of left anterior descending artery of a cardiac allograft at a branching site at baseline (A) and one year
after transplantation (B) showing severe intimal progression. CMIT change in maximal intimal and medial thickness over one year; IVUS intravascular
ultrasound; MIT  maximal intimal thickness.
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the fibrosis group. Acute vascular rejection is characterized
by a cascade of inflammatory reactions associated with
myocardial ischemic necrosis, vascular endothelial injury
and intravascular immune complex formation with deposi-
tion of immunoglobulin, usually IgM, as well as comple-
ments such as C1q or C3 (19). Based on the histology
findings, the study group of 140 patients was divided into
the following four groups:
1. Ischemia group (n  24): patients who developed peri-
transplant ischemia uncomplicated by fibrosis or vascular
rejection (negative immunofluorescence).
2. Fibrosis group (n  62): patients who developed peri-
transplant ischemia followed by interstitial fibrosis in the
absence of vascular rejection (negative immunofluores-
cence).
3. Vascular group (n  22): patients with evidence of acute
vascular rejection confirmed by immunofluorescence;
ischemic/fibrotic injury was evident in 82% (18/22) of
these patients.
4. Nonischemic group (n  32): patients with no evidence
of peritransplant ischemia, fibrosis or vascular rejection.
Average biopsy score was calculated in each patient as the
sum of numerical values assigned to each International
Society of Heart and Lung Transplantation grade of rejec-
tion, divided by the total number of biopsies during the first
year after transplantation.
Quantitative flow cytometry crossmatching. Using pre-
transplant sera, three-color flow cytometry crossmatching
(FCXM) was performed as previously described (20) to
quantitate antidonor IgG reactions against donor B and T
lymphocytes. All reactions were compared with normal
control sera. A shift from control values of 500 molecules
of equivalent soluble fluorochrome was considered positive
for T-cell reactions and 2,000 molecules of equivalent
soluble fluorochrome was considered positive for B-cell
reactions. Positive reactions against both T and B cells were
considered to be against class I antigens, and positive
reactions against B cells only was considered to be against
human lymphocyte antigens (HLA) class II antigens.
Immunosuppressive treatment. All patients were main-
tained on prednisone. The maintenance immunosuppressive
regimens are shown in Table 1. Twenty percent of grade 2
and all grade 3A rejection episodes were treated with
steroid pulse therapy.
Statistical analysis. Quantitative data are presented as
mean  SD. The analysis of variance (ANOVA) or the
chi-square test was used to find significant differences
among the different groups. To account for potential devi-
ations from normal distribution, nonparametric testing
using Kruskal-Wallis test was used when appropriate.
Time-related analysis was conducted using the method of
Kaplan and Meier, and the log-rank (Mantel-Cox) test was
used to test the equality of freedom from a combined end
point of death, retransplantation and graft failure in the four
groups stratified by findings on endomyocardial biopsy
described previously. Cox proportional hazards regression
was used to identify the risk factors for the combined end
point. Results were reported as hazard ratio, 95% confidence
intervals and p values. A p value0.05 was considered to be
significant for all analyses.
RESULTS
The characteristics of the 140 patients in four groups are
displayed in Table 1. The donor age was significantly
Figure 2. A section of the myocardium (H&E stain) from a patient with ischemic injury complicated by the development of interstitial fibrosis.
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greater in the fibrosis group of patients than in the other
groups. Brain injury was more likely to be the cause of donor
death in the fibrosis group than in the other groups. The
recipient age, etiology of heart disease in the recipient, the
use of left ventricular assist device and ischemia time were
similar in the four groups of patients. Tacrolimus-based
therapy tended to be more commonly used in the vascular
rejection group than in any other.
Development of allograft vasculopathy. The progression
of vasculopathy in the four groups of patients as measured
by the change in maximal intimal and medial thickness
(CMIT) is represented in Figure 3. Compared with patients
in the nonischemic group, patients in the fibrosis group had
a significant increase in intimal thickness, which was com-
parable to that in patients with vascular rejection (vascular
group).
Long-term outcome. During a mean follow-up period of
67  19 months, 16% (23/140) of the patients died and 8%
(12/140) developed graft failure, with one of these patients
requiring a retransplant. Patients with graft failure had left
ventricular dysfunction with symptomatic heart failure and a
mean left ventricular ejection fraction of 28  8%. The
majority of deaths were related to allograft vasculopathy. In
a univariate Cox regression, recipient age, histopathological
groups, donor age, ischemia time, donor cause of death and
HLA crossmatch were tested, and histopathological group
was found to be the only significant factor in determining
morbidity and mortality. The Kaplan-Meier seven-year
event-free survival in the different histopathological groups
is shown in Figure 4. The patients in the fibrosis group had
a poor outcome. Risk of death or allograft failure for
patients in the fibrosis group was almost four times higher
compared with that for patients in the nonischemic group
(hazard ratio  3.8; CI 1.14 to 12.8; p  0.03) and five
times higher than for patients in the ischemia group (hazard
ratio  4.95; CI 1.16 to 21.3; p  0.03).
Cellular rejection. Patients in the fibrosis group had the
lowest average episodes of grade 3A rejection (Fig. 5) and
Table 1. Baseline Characteristics
Ischemia Fibrosis Nonischemic Vascular p Value
n  24 62 32 22
Donor age (yrs) 27  10 37  11 29  12 29  11 0.001
Recipient age (yrs) 49  11 53  11 48  11 52  8 0.08
CNS-donor death 9 (38%) 30 (48%) 8 (25%) 5 (23%) 0.06
Etiology
Dilated CM 11 (46%) 22 (35%) 15 (47%) 9 (41%) NS
Ischemic CM 13 (56%) 40 (65%) 17 (53%) 13 (59%) NS
LVAD 6 (25%) 15 (24%) 9 (28%) 3 (14%) NS
Ischemia time (min) 143  48 145  50 136  46 142  43 NS
Immunosuppression
AZA/CSA/pred 11 (46%) 26 (42%) 12 (38%) 7 (32%) NS
MMF/CSA/pred 9 (38%) 33 (53%) 17 (53%) 10 (45%) NS
FK/MMF/pred 4 (16%) 3 (5%) 3 (9%) 5 (23%) 0.09
AZA  azathioprine; CM  cardiomyopathy; CNS  donor death caused by brain injury; CSA  cyclosporine; FK 
tacrolimus; LVAD  left ventricular assist device as a bridge to transplant; MMF  mycophenolate mofetil; NS  not
significant; pred  prednisone.
Figure 3. Bar diagram showing extent of progression of coronary vasculopathy in the first year after transplantation (as indicated by the change in maximal
intimal and medial thickness, CMIT) in the different patient groups.
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the lowest average biopsy score (Fig. 6) compared with the
other groups. Patients with vascular rejection, as expected,
had the highest incidence of cellular rejection episodes.
Donor-specific FCXM. The fibrosis group had the lowest
incidence of positive HLA (class I or class II) donor-specific
cross matches (Fig. 7) and tended to have reduced amounts
of IgG binding to T- (Fig. 8) and B- (Fig. 9) cell
lymphocytes from the donors.
Coronary angiography. Among patients who survived be-
yond three years after transplant and who were able to undergo
cardiac catheterization (depending on renal function), coronary
angiography data were available on 109 patients. Advanced
coronary vasculopathy (50% obstruction) was more common
in the fibrosis group than in any other (Table 2).
DISCUSSION
Early endomyocardial fibrosis has been described in trans-
plant animal models and human allograft recipients and was
linked to peritransplant ischemia (21,22). In a recent study
on serial endomyocardial biopsies on 50 cardiac transplant
patients followed over five years, Armstrong and his col-
leagues (23) showed that myocardial fibrosis develops early
and remains modestly elevated two months after transplant,
indicating that peritransplant factors might be responsible
for this fibrotic process. Pickering et al. (22) showed that
cardiac allograft fibrosis may be identified shortly after
transplantation and is dependent on the total ischemia
duration. In our study, 61% (86/140) of transplant recipi-
ents showed evidence of ischemic injury on their endomyo-
cardial biopsies soon after transplantation, and 72% (62/86)
of these patients developed fibrosis on successive biopsies
(within one to four weeks of ischemia). We studied the
relationship of ischemia and fibrosis to development of
coronary vasculopathy, acute cellular rejection and the
impact of this ischemia and fibrosis on long-term survival in
heart transplant recipients.
Figure 4. Kaplan-Meier seven-year event-free survival in the different patient groups.
Figure 5. Bar diagram showing average episodes of acute cellular rejection 3A (during the first year of transplantation) in the different patient groups.
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Our results indicate that patients with peritransplant
myocardial ischemia followed by fibrosis clearly showed an
increased incidence of progression of coronary vasculopathy
confirmed by IVUS (at one year) and subsequent cardiac
catheterization. Surprisingly, these patients had the least
cellular rejection and antidonor HLA presensitization, in-
dicating factors other than an antiallograft immune response
are responsible for the progression of vasculopathy. Peeters
and colleagues (24) found an inverse relationship, similar to
our findings, between acute cellular rejection and portal
fibrosis in pediatric liver transplant patients.
Ischemia at the time of transplantation has been associ-
ated with direct endothelial injury. Billingham et al. (25)
compared the histological findings at the time of transplan-
tation in hearts procured distantly (mean ischemia time 154
min) and hearts procured locally (mean ischemia time 49
min) and found severe capillary endothelial cell damage in
the distantly obtained donor hearts, compared with almost
no endothelial cell damage in the on-site donor hearts. In an
experimental model of rat renal allograft (26), prolonged
ischemia was associated with chronic rejection (vasculopa-
thy) that was not due to the increased intensity of antial-
lograft immune response. Injured endothelial cells could, in
turn, promote atherosclerosis through a number of mecha-
nisms, including the adherence of platelets, release of
growth factors and cytokines, expression of adhesion mol-
ecules and proliferation of vascular smooth muscle cells
(27–29).
Our study identified a subgroup of patients with peri-
transplant ischemia complicated by fibrosis who had rapid
Figure 6. Bar diagram showing average biopsy score (during the first year of transplantation) in the different patient groups.
Figure 7. Bar diagram showing percentage of patients with positive human lymphocyte antigens crossmatch in the different patient groups. FCXM  flow
cytometry cross match.
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progression of vasculopathy, a decreased rate of cellular
rejection and a poor seven-year event-free survival. Com-
pared with the other three groups, the fibrosis group was
associated with higher donor age, and the donor cause of
death was more likely to be related to brain injury. The
mechanism is not clear. Increased donor age (1) has been
shown to be associated with the development of severe
coronary vasculopathy. Brain-injury related donor cause of
death has also been shown to influence the outcome in heart
transplants (30). In our study there was no difference in
ischemia times among the groups, highlighting the fact that
graft ischemia time may not be the best predictor of
peritransplant ischemic injury.
Study limitations. We used IVUS to assess the extent of
progression of vasculopathy. Our study was based on match-
ing site analysis and thus may be subject to selection bias.
Although volumetric analysis with motorized pull back
would be the most suitable approach to compare serial
changes (31), our study was conducted with manual pull
back, and thus volumetric analysis could not be applied.
Another limitation of the study is that the design has an
internal selection bias for outcome because only patients
who completed IVUS study at one year were evaluated;
hence, only patients who survived the first year after
transplantation were followed. Therefore, the mortality does
not reflect the natural course of the different categories since
the time of transplant.
Conclusions. We conclude that myocardial ischemia in the
peritransplant period complicated by fibrosis is associated
with increased progression of allograft coronary vasculopa-
thy and a poor long-term outcome. This effect may be
mediated by factors other than an increase in the intensity of
Figure 8. Bar diagram showing quantitative T-cell flow cytometry in the different patient groups. FCXM  flow cytometry cross match.
Figure 9. Bar diagram showing quantitative B-cell flow cytometry in the different patient groups. FCXM  flow cytometry cross match.
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allograft immune response because the incidence of humoral
presensitization and acute cellular rejection was low in this
group of patients.
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Table 2. Cardiac Catheterization Data
Ischemia Fibrosis Nonischemic Vascular p Value
n  22 47 25 15
Advanced vasculopathy 2 (9%) 15 (32%) 0 (0%) 1 (6%) 0.001
Moderate 8 0 0
Severe 2 7 0 1
Mild vasculopathy 6 (27%) 10 (21%) 12 (48%) 7 (47%) NS
Normal coronaries 14 (64%) 22 (47%) 13 (52%) 7 (47%) NS
NS  not significant.
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